One-third to one-half of kidney disease in type 2 diabetes patients is non-diabetic in origin, requiring biopsy-guided treatment that combines renoprotective therapies like GLP-1 receptor agonists (HR 0.76) with disease-specific immunomodulation.
33-50% of kidney disease is non-diabeticIn type 2 diabetes patients, a substantial proportion have non-diabetic kidney pathology requiring biopsy-guided treatment alongside universal renoprotection with GLP-1RAs, SGLT2i, and other agents
What the researchers found
NDKD affects one-third to one-half of T2DM patients with kidney disease. IgA nephropathy dominates in Asian populations (25-43%), while membranous nephropathy (20-30%) and FSGS (18-25%) are more common in Western cohorts. Clinical predictors include absence of diabetic retinopathy (OR 0.15 for DKD), diabetes <5 years (OR 5.8 for NDKD), hematuria (OR 7.2), and rapid eGFR decline >5 mL/min/year (OR 4.3). For renoprotection: SGLT2 inhibitors show HR 0.61-0.72, GLP-1 RAs ~0.76, and MRAs ~0.82. AI-assisted histopathology achieves AUC 0.91 for diagnosis.
Why it matters
Misdiagnosing non-diabetic kidney disease as diabetic nephropathy leads to missed treatment opportunities — these patients need specific immunosuppressive therapies. At the same time, renoprotective peptide-based therapies like GLP-1 receptor agonists benefit kidney function regardless of the underlying cause. This review provides a framework for integrating biopsy-guided precision medicine with universal renoprotective strategies, including the growing role of GLP-1RAs in kidney protection.
How the study worked
Narrative review of PubMed, EMBASE, and Scopus (January 2020-December 2024), including systematic reviews, meta-analyses, RCTs, cohort studies, and clinical guidelines addressing NDKD in diabetes.
What this study cannot tell us
This is a narrative review without systematic methodology or meta-analysis. The prevalence estimates for NDKD vary widely across studies and populations. The GLP-1RA hazard ratio cited (~0.76) represents pooled evidence that may not apply equally to all NDKD subtypes. Kidney biopsy, while the gold standard, carries procedural risks and is not appropriate for all patients. AI-assisted diagnostic tools are promising but not yet widely available.
How to read the evidence
This is a comprehensive narrative review synthesizing systematic reviews, meta-analyses, and RCTs from a 5-year literature search. The evidence cited for individual therapies (including GLP-1RAs) comes from high-quality sources, though the review itself does not perform new pooled analyses.
When this study was published
Published in 2026 with literature through December 2024, this review captures the current state of NDKD management and the latest evidence for renoprotective therapies including GLP-1 receptor agonists.
The bigger picture
GLP-1 receptor agonists are rapidly establishing themselves as kidney-protective agents alongside SGLT2 inhibitors and mineralocorticoid receptor antagonists. This review places GLP-1RAs within the broader nephrology toolkit and highlights that their benefits extend across different kidney disease pathologies — not just diabetic nephropathy. As the understanding of kidney disease in diabetes becomes more nuanced, the role of peptide-based therapies as part of a multi-drug renoprotective strategy is increasingly clear.
Questions still open
- Do GLP-1 receptor agonists provide equal renoprotection across different non-diabetic kidney disease subtypes?
- Can non-invasive biomarkers and AI tools eventually replace kidney biopsy for identifying NDKD in diabetic patients?
- What is the optimal combination and sequencing of GLP-1RA, SGLT2i, and MRA for maximum kidney protection?
Common questions
Can kidney disease in diabetes be caused by something other than the diabetes?
How do GLP-1 drugs protect the kidneys?
Read the original research
Non-diabetic Kidney Disease in Type 2 Diabetes: From Kidney Biopsy to Precision Medicine.
Cureus, 18(1), e100716
Citation
Sreedharan, Sreenath; M K, Mohandas; K B, Vismaya; Raju, Nikhil. (2026). Non-diabetic Kidney Disease in Type 2 Diabetes: From Kidney Biopsy to Precision Medicine.. Cureus, 18(1), e100716. https://doi.org/10.7759/cureus.100716